Literature DB >> 17498853

Investigation of mumps vaccine failures in Minsk, Belarus, 2001-2003.

Alena V Atrasheuskaya1, Elena M Blatun, Michail V Kulak, Alina Atrasheuskaya, Igor A Karpov, Steven Rubin, George M Ignatyev.   

Abstract

The purpose of this study was to investigate mumps vaccine failures (VF) in a highly vaccinated population of Minsk, Belarus, and to investigate a possible role for virus strain-specific immunity. During our 3-year study period, 22 adults were admitted to the Infectious Diseases Hospital in Minsk with a diagnosis of mumps. A genotype H1 mumps virus (MuV) strain was identified in all patients. Of 15 patients from whom the paired sera were collected, 9 were confirmed to have been previously vaccinated. Serological examinations indicated primary VF in seven of these cases and secondary VF in two. Despite almost all vaccinated patients possessing MuV specific IgG, few possessed neutralizing antibody to the vaccine strain and titers were nominal. Importantly, none of the sera were able to neutralize a genotype H MuV strain. Our results demonstrate the importance of assaying for neutralizing antibody and support the assertion that antigenic differences between wild type and vaccine MuV strains may play a role in cases of breakthrough infection in vaccinees.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17498853     DOI: 10.1016/j.vaccine.2007.04.020

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Characterization of mumps viruses circulating in Mongolia: identification of a novel cluster of genotype H.

Authors:  Minoru Kidokoro; Rentsengiin Tuul; Katsuhiro Komase; Pagbajab Nymadawa
Journal:  J Clin Microbiol       Date:  2011-03-16       Impact factor: 5.948

2.  Molecular epidemiological evaluation of the recent resurgence in mumps virus infections in Ireland.

Authors:  Michael J Carr; Eibhlín Moss; Allison Waters; Jonathan Dean; Li Jin; Suzie Coughlan; Jeff Connell; William W Hall; Jaythoon Hassan
Journal:  J Clin Microbiol       Date:  2010-07-21       Impact factor: 5.948

3.  A 176 amino acid polypeptide derived from the mumps virus HN ectodomain shows immunological and biological properties similar to the HN protein.

Authors:  Emma Herrera; Patricia Barcenas; Rubicela Hernández; Alfonso Méndez; Guillermo Pérez-Ishiwara; Blanca Barrón
Journal:  Virol J       Date:  2010-08-20       Impact factor: 4.099

4.  Immune responses to mumps vaccine in adults who were vaccinated in childhood.

Authors:  Rima Hanna-Wakim; Linda L Yasukawa; Phillip Sung; Ann M Arvin; Hayley A Gans
Journal:  J Infect Dis       Date:  2008-06-15       Impact factor: 5.226

5.  Circulation of mumps virus genotypes in Spain from 1996 to 2007.

Authors:  J E Echevarría; A Castellanos; J C Sanz; C Pérez; G Palacios; M V Martínez de Aragón; I Peña Rey; M Mosquera; F de Ory; E Royuela
Journal:  J Clin Microbiol       Date:  2010-01-27       Impact factor: 5.948

6.  Reemergence of mumps.

Authors:  Kyong Min Choi
Journal:  Korean J Pediatr       Date:  2010-05-31

Review 7.  Knowledge gaps persist and hinder progress in eliminating mumps.

Authors:  R Ramanathan; E A Voigt; R B Kennedy; G A Poland
Journal:  Vaccine       Date:  2018-05-18       Impact factor: 4.169

8.  Molecular characteristics of mumps viruses isolated in Taiwan from 2006 to 2016.

Authors:  Wen-Yueh Cheng; Ming-Tsan Liu
Journal:  Heliyon       Date:  2018-02-08

Review 9.  Mumps Outbreaks in Vaccinated Populations-Is It Time to Re-assess the Clinical Efficacy of Vaccines?

Authors:  Anna R Connell; Jeff Connell; T Ronan Leahy; Jaythoon Hassan
Journal:  Front Immunol       Date:  2020-09-18       Impact factor: 7.561

10.  Development and Use of an Endpoint Titration Assay To Characterize Mumps IgG Avidity following Measles, Mumps, and Rubella Vaccination and Wild-Type Mumps Infection.

Authors:  Sara Mercader; Marcia McGrew; Sun B Sowers; Nobia J Williams; William J Bellini; Carole J Hickman
Journal:  mSphere       Date:  2018-09-12       Impact factor: 4.389

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.